Transcatheter and Surgical Ductus Arteriosus Closure in Very Low Birth Weight Infants: 2018–2022

Abstract

BACKGROUND AND OBJECTIVE The optimal patent ductus arteriosus (PDA) closure method in very low birth weight (VLBW) infants is uncertain. In 2019, the first transcatheter occlusion device was approved in the United States for infants ≥700 g. We described survival and short-term outcomes among VLBW infants who underwent transcatheter or surgical PDA closure (2018–2022). METHODS Vermont Oxford Network members submitted data on infants born from 401 to 1500 g or 22 to 29 weeks’ gestational age. Adjusted risk ratios (aRR) for survival, length of stay (LOS), prematurity complications, and discharge support were used to compare transcatheter versus surgical closure. Subgroup analyses were conducted for infants with birth weight ≥700 g and born in 2020–2022. RESULTS Overall, 6410 of 216 267 infants at 726 hospitals received invasive PDA treatment. Transcatheter closure increased from 29.8% in 2018 to 71.7% in 2022. VLBW infants undergoing transcatheter closure had higher survival (adjusted rate ratio [aRR] 1.03; 1.02–1.04) with similar LOS (aRR 1.00; 0.97–1.03), neonatal complications (aRR 1.00; 0.98–1.01), and receipt of discharge support (aRR 0.94; 0.89–1.01). In subgroup analyses, survival (aRR 1.02; 1.00–1.04) and discharge support (aRR 0.90; 0.81–1.01) were similar between groups, whereas selected neonatal complications (aRR 0.95; 0.93–0.98) and LOS (aRR 0.95; 0.90–0.99) were lower after transcatheter closure. CONCLUSIONS Transcatheter PDA closure in VLBW infants was increasingly used after 2018. Selected short-term outcomes for infants receiving transcatheter closure may be more favorable, compared with surgical, and warrants further clinical investigation.